Literature DB >> 10893287

Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used.

K M McMasters1, T M Tuttle, D J Carlson, C M Brown, R D Noyes, R L Glaser, D J Vennekotter, P S Turk, P S Tate, A Sardi, P B Cerrito, M J Edwards.   

Abstract

PURPOSE: Previous studies have demonstrated the feasibility of sentinel lymph node (SLN) biopsy for nodal staging of patients with breast cancer. However, unacceptably high false-negative rates have been reported in several studies, raising doubt about the applicability of this technique in widespread surgical practice. Controversy persists regarding the optimal technique for correctly identifying the SLN. Some investigators advocate SLN biopsy using injection of a vital blue dye, others recommend radioactive colloid, and still others recommend the use of both agents together. PATIENTS AND METHODS: A total of 806 patients were enrolled by 99 surgeons. SLN biopsy was performed by single-agent (blue dye alone or radioactive colloid alone) or dual-agent injection at the discretion of the operating surgeon. All patients underwent attempted SLN biopsy followed by completion level I/II axillary lymph node dissection to determine the false-negative rate.
RESULTS: There was no significant difference (86% v 90%) in the SLN identification rate among patients who underwent single- versus dual-agent injection. The false-negative rates were 11.8% and 5.8% for single- versus dual-agent injection, respectively (P <.05). Dual-agent injection resulted in a greater mean number of SLNs identified per patient (2. 1 v 1.5; P <.0001). The SLN identification rate was significantly less for patients older than 50 years as compared with that of younger patients (87.6% v 92.6%; P =.03). Upper-outer quadrant tumor location was associated with an increased likelihood of a false-negative result compared with all other locations (11.2% v 3. 9%; P <.05).
CONCLUSION: In multi-institutional practice, SLN biopsy using dual-agent injection provides optimal sensitivity for detection of nodal metastases. The acceptable SLN identification and false-negative rates associated with the dual-agent injection technique indicate that this procedure is a suitable alternative to routine axillary dissection across a wide spectrum of surgical practice and hospital environments.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893287     DOI: 10.1200/JCO.2000.18.13.2560

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  109 in total

Review 1.  What is the accuracy of sentinel lymph node biopsy for gastric cancer? A systematic review.

Authors:  Roberta Cardoso; Alina Bocicariu; Matthew Dixon; Lavanya Yohanathan; Rajini Seevaratnam; Lucy Helyer; Calvin Law; Natalie G Coburn
Journal:  Gastric Cancer       Date:  2012-01-20       Impact factor: 7.370

Review 2.  Technology as a force for improved diagnosis and treatment of breast disease.

Authors:  Claire M B Holloway; Alexandra Easson; Jaime Escallon; Wey Liang Leong; May Lynn Quan; Michael Reedjik; Frances C Wright; David R McCready
Journal:  Can J Surg       Date:  2010-08       Impact factor: 2.089

Review 3.  Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.

Authors:  Tari A King; Monica Morrow
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

4.  A Randomized Trial Comparing the Efficacy of Methylene Blue Dye Alone Versus Combination of Methylene Blue Dye and Radioactive Sulfur Colloid in Sentinel Lymph Node Biopsy for Early Stage Breast Cancer Patients.

Authors:  Vikas Gupta; Kvvn Raju; T Subramanyeshwar Rao; C K Naidu; Vipin Goel; Nisha Hariharan; Ramachandra Nagarajuch; B Madhunarayana
Journal:  Indian J Surg Oncol       Date:  2019-12-10

Review 5.  Sentinel lymph node mapping for primary breast cancer.

Authors:  Lori L Wilson; Armando E Giuliano
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

6.  The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project.

Authors:  D Lawrence Wickerham; Joseph P Costantino; Eleftherios P Mamounas; Thomas B Julian
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

7.  Contralateral or bilateral lymph drainage revealed by breast lymphoscintigraphy.

Authors:  Giuseppe Trifirò; Laura Ravasi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02       Impact factor: 9.236

8.  Noninvasive photoacoustic identification of sentinel lymph nodes containing methylene blue in vivo in a rat model.

Authors:  Kwang Hyun Song; Erich W Stein; Julie A Margenthaler; Lihong V Wang
Journal:  J Biomed Opt       Date:  2008 Sep-Oct       Impact factor: 3.170

9.  (68)Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes.

Authors:  Renata Madru; Thuy A Tran; Johan Axelsson; Christian Ingvar; Adnan Bibic; Freddy Ståhlberg; Linda Knutsson; Sven-Erik Strand
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

10.  Sentinel lymph node biopsy in early-stage breast cancer patients: improved survival through better staging?

Authors:  Pamela Meiers; Tulin Cil; Ulrich Guller; Markus Zuber
Journal:  Langenbecks Arch Surg       Date:  2012-12-11       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.